When.com Web Search

Search results

1. Results From The WOW.Com Content Network

2. UW Health to use new device that sits cancer patients upright ...

   www.aol.com/news/uw-health-device-sits-cancer...

   A rendering of a new radiation therapy device, developed by Middleton-based Leo Cancer Care, that allows patients to get radiation while sitting upright. UW Health will become the first in the ...

3. mRNA Technology Promises To Make A Long-Time Coming Turning ...

   www.aol.com/mrna-technology-promises-long-time...

   The beauty of mRNA technology is that it opens the door to a more personalized and effective treatment as messenger RNA instructs the patient’s cells how to combat diseases like cancer ...

4. US FDA mandates label updates on CAR-T cancer therapies - AOL

   www.aol.com/news/us-fda-mandates-label-updates...

   (Reuters) - The U.S. Food and Drug Administration said on Thursday cancer therapies that use CAR-T technology will require changes to the so-called "boxed warning" to highlight the serious risk of ...

5. News, Politics, Sports, Mail & Latest Headlines - AOL.com

   w.main.welcomescreen.aol.com

   Discover the latest breaking news in the U.S. and around the world — politics, weather, entertainment, lifestyle, finance, sports and much more.

6. Hadiyah-Nicole Green - Wikipedia

   en.wikipedia.org/wiki/Hadiyah-Nicole_Green

   Hadiyah-Nicole Green (1981-) is an American medical physicist, known for the development of a method using laser-activated nanoparticles as a potential cancer treatment. [1] [2] [3] She is one of 66 black women to earn a Ph.D. in physics in the United States between 1973 and 2012, [4] and is the second black woman and the fourth black person ever to earn a doctoral degree in physics from The ...

7. Autogene cevumeran - Wikipedia

   en.wikipedia.org/wiki/Autogene_cevumeran

   At the end of the study, the responders hadn't reached the 18-month RFS endpoint, meaning that their cancer hadn't recurred in the 18 months following treatment, while the non-responders had a median RFS of 13.4 months. The authors concluded that, given the preliminary evidence of efficacy and safety, an international phase 2 trial was imminent.

8. Transgene (company) - Wikipedia

   en.wikipedia.org/wiki/Transgene_(company)

   Transgene’s portfolio consists of four products currently in clinical development. Its lead product TG4050, a neoantigen individualized therapeutic cancer vaccine is currently being developed in a randomized Phase I/II trial in the adjuvant treatment of head and neck cancer. The company is listed on the regulated market of Euronext in Paris [1].

9. The Covid Era Tech Promises To Reinvent Cancer Treatment - AOL

   www.aol.com/finance/covid-era-tech-promises...

   Pfizer Inc (NYSE: PFE) made a promise to outdo cancer, joining its Covid vaccine-peer, Moderna Inc (NASDAQ: MRNA) in turning to oncology for its next growth story.